Performance of MRgFUS in pediatric patients has not been well characterized. Retrospective review of 21 MRgFUS treatments in 9 patients below the age of 18 shows significant reduction in viable tumor volume in a variety of indications including desmoid tumors, vascular malformations, and osteoid osteoma. MRgFUS is an effective ablative therapy in children that warrants further investigation.
This abstract and the presentation materials are available to members only; a login is required.